Patents by Inventor Timothy P. Day

Timothy P. Day has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods of treating ocular diseases
    Patent number: 12310997
    Abstract: The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: May 27, 2025
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Leah C. Byrne, Timothy P. Day, John G. Flannery
  • Compositions and Methods of Treating Ocular Diseases
    Publication number: 20240091378
    Abstract: The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
    Type: Application
    Filed: February 10, 2023
    Publication date: March 21, 2024
    Inventors: David V. Schaffer, Leah C. Byrne, Timothy P. Day, John G. Flannery
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSIDS AND METHODS OF USE THEREOF
    Publication number: 20200121746
    Abstract: The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
    Type: Application
    Filed: June 28, 2018
    Publication date: April 23, 2020
    Inventors: David V. Schaffer, Leah C. Byrne, Timothy P. Day, John G. Flannery